U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H28FN7O
Molecular Weight 437.5131
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZD-5597

SMILES

CN[C@H]1CCN(C1)C(=O)C2=CC=C(NC3=NC=C(F)C(=N3)C4=CN=C(C)N4C(C)C)C=C2

InChI

InChIKey=NTSDIJMNXYJJNG-SFHVURJKSA-N
InChI=1S/C23H28FN7O/c1-14(2)31-15(3)26-12-20(31)21-19(24)11-27-23(29-21)28-17-7-5-16(6-8-17)22(32)30-10-9-18(13-30)25-4/h5-8,11-12,14,18,25H,9-10,13H2,1-4H3,(H,27,28,29)/t18-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H28FN7O
Molecular Weight 437.5131
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

AZD-5597 is potent imidazole pyrimidine amide CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines. AZD-5597 exhibited excellent aqueous solubility, photostability, hydrolytic stability, plasma stability and the lack of CYP inhibition. In nude mice implanted subcutaneously with SW620 human colon adenocarcinoma cells, AZD-5597 (15 mg/kg, dosed intermittently for 3 weeks, ip) inhibited tumor volume by 55%. The overall profile of AZD-5597 indicated that it was suitable for further development as an iv agent.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.0 nM [IC50]
2.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

Nude mice were treated intermittently (Monday, Wednesday, Friday) for 3 weeks at 15 mg/kg
Route of Administration: Intraperitoneal
The colorectal cancer cell lines LoVo were used for activity evaluation. Cells were plated in 96-well plates with medium containing 0.125% FBS for 24 h and then treated with medium containing 10% FBS and the test compound (AZD-5597) at various concentrations, and incubated for 48 h. Compounds activity was evaluated by Bromodeoxyuridine assay.
Substance Class Chemical
Created
by admin
on Sat Dec 16 07:59:42 GMT 2023
Edited
by admin
on Sat Dec 16 07:59:42 GMT 2023
Record UNII
N7855W19GY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZD-5597
Common Name English
METHANONE, (4-((5-FLUORO-4-(2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL)-2-PYRIMIDINYL)AMINO)PHENYL)((3S)-3-(METHYLAMINO)-1-PYRROLIDINYL)-
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID20239012
Created by admin on Sat Dec 16 07:59:42 GMT 2023 , Edited by admin on Sat Dec 16 07:59:42 GMT 2023
PRIMARY
FDA UNII
N7855W19GY
Created by admin on Sat Dec 16 07:59:42 GMT 2023 , Edited by admin on Sat Dec 16 07:59:42 GMT 2023
PRIMARY
CAS
924641-59-8
Created by admin on Sat Dec 16 07:59:42 GMT 2023 , Edited by admin on Sat Dec 16 07:59:42 GMT 2023
PRIMARY
PUBCHEM
16113484
Created by admin on Sat Dec 16 07:59:42 GMT 2023 , Edited by admin on Sat Dec 16 07:59:42 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY